Project Grant K22CA285824
Award Date 9/1/25
Completion Date 8/31/28
Dollars Obligated $170K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
- This $147,486 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research by Baylor College of Medicine to investigate the role of the HP1BP3 protein in regulating chromatin remodeling and its impact on tumor growth in high-grade glioma, the most common malignant adult brain cancer. The research aims to define epigenomic dysregulations that promote glioma growth and determine the mechanisms by which these alterations drive tumorigenesis....
- This $484,803 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research by Mayo Clinic to elucidate the genetics underlying glioma risk and outcomes. The project aims to leverage germline and somatic genetic data to: Evaluate the clinical utility of germline variants associated with glioma risk and specific molecular subtypes through polygenic risk models. Determine if germline variants can predict the presence of clinically...
- The Project Grant award of $412,499.00 from the Department of Health and Human Services National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), supports research on the molecular mechanisms of mutant IDH inhibition and DNA damage in IDH-mutant glioma. The project aims to use a newly developed genetically engineered mouse model of IDH-mutant grade 3 astrocytoma to understand...
- This federal Project Grant award of $109,076.00, awarded by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) on December 17, 2025, supports research to immuno-modulate diffuse midline glioma, an aggressive pediatric brain tumor, through epigenetic reprogramming. The project, led by the University of Miami, aims to advance scientific understanding and develop new treatment approaches for this deadly disease. The 4-year project period runs through September 1, 2029. The...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) provides $144,981 to the University of California, San Diego (UC San Diego) to characterize the role of extrachromosomal DNA (ecDNA) in shaping the heterogeneity and plasticity of glioblastoma (GBM) cellular states. The award period runs from September 3, 2025 to August 31, 2027. The project aims to determine how ecDNA, which are large circular DNA elements harboring oncogenes,...
- This federal Project Grant award of $460,940 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research conducted by the University of Texas MD Anderson Cancer Center to investigate how genetic risk factors for glioma, a type of brain cancer, impact neurodevelopmental processes and potentially promote tumor formation. The research leverages human...
- This federal Project Grant award of $135,513, provided by the National Cancer Institute under the Cancer Research Manpower (CFDA 93.398) program, supports research to elucidate the transcriptional mechanisms underlying cognitive impairment induced by cancer therapies, a critical issue affecting cancer survivors. The research, conducted by Beth Israel Deaconess Medical Center, Inc., a prominent academic medical center in Boston, Massachusetts, aims to identify candidate transcription factor...
- This $292,028 Project Grant awarded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to investigate the mechanisms by which oncogene amplification leads to genome instability and the development of therapy-resistant cancer clones. The research will be conducted by the Sloan-Kettering Institute for Cancer Research in New York and is scheduled to run from August 1, 2025 to July 31, 2030. Using single-cell genomic sequencing techniques, the project aims...
- This $1,449,000 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) supports research to study the fundamental regulation of extrachromosomal DNA (ecDNA) in cancer genomes. The project aims to develop new live-cell chromatin labeling strategies and integrate advanced imaging, synthetic genome engineering, and optical/genetic perturbation to systematically investigate how ecDNA orchestrates massive...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $230,010 to the University of Chicago to develop and apply a novel epigenome sequencing platform called "Glycosylase-Implemented Epigenome Sequencing" (GLIMP-SEQ). The goal is to enable highly sensitive and accurate profiling of 5-methylcytosine (5mC), a key epigenetic marker, in degraded clinical samples such as formalin-fixed, paraffin-embedded tissues and cell-free DNA....